You’re on a panel at DPHARM 2024 focused on advancing scalability and operationalizing digital endpoints in clinical trials. What can people expect from this discussion? We’re looking at how we can ...
Digital biomarker to enhance precision, reduce patient burden and boost efficiency of global Phase 2 trial of NEU-411 in early Parkinson’s disease SOUTH SAN FRANCISCO, Calif.--(BUSINESS ...
While a lot of researchers claim they are capturing digital biomarker data, they may in fact be collecting clinical outcomes assessment (COA) data according to some US regulators. To clarify the ...
WASHINGTON, D.C., March 19, 2026 (GLOBE NEWSWIRE) -- NeuroRPM, a digital health company focused on Parkinson’s disease monitoring, today announced that its FDA-cleared wearable platform will be used ...
This Collection seeks to advance the discussion on noninvasive biomarkers by exploring their applications and implications across different data landscapes, namely real-world data (RWD) and clinical ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results